J Korean Med Assoc.  2005 Jul;48(7):641-645. 10.5124/jkma.2005.48.7.641.

Treatment of Normal-tension Glaucoma

• Kim CS

• KMID: 2183591
• DOI: http://doi.org/10.5124/jkma.2005.48.7.641

Abstract

Normal tension glaucoma (NTG) is a disorder showing the characteristic optic nerve head damage and visual field defect with a normal intraocular pressure (IOP) and open anterior chamber angle, without any other disorders that may induce a damage to the optic nerve head and visual field. A disturbance in the vascular supply to the optic nerve head is thought to be the main etiologic factor in this disorder. A thirty percent reduction of IOP from the baseline can delay or prevent the disease progress of glaucoma, and the treatment of NTG is focused on relieving any vascular disturbance to the optic nerve head and reducing IOP. The target pressure in NTG should be individualized in each patient by age, presence of any systemic vascular disorder, the degree of optic disc damage, and response to anti-glaucoma medications. It should also be carefully and regularly re-evaluated during follow-up. Since most patients with NTG are old, the selection of anti-glaucoma medication needs a careful consideration of the systemic status of the patient. Pilocarpine effectively reduces IOP, but has limitations from side effects including miosis. Nonselective beta-blocking agents may induce serious systemic side effects and can reduce the perfusion pressure to the optic nerve head. Brimonidine reduces the aqueous inflow, increases the uveoscleral outflow, and is known to have a potential neuroprotective effect. Betaxolol and dorzoldamide are known to increase the ocular blood flow and have a protective effect from optic nerve damage. Oral carbonic anhydrase inhibitor may be effective, if systemic adverse effects can be tolerated. Prostaglandins may reduce IOP below the level of episcleral venous pressure, but their long-term side effects have not been fully evaluated to date. Laser trabeculoplasty can reduce IOP, but not sufficiently in many instances. To reduce IOP sufficiently enough to halt the progression of glaucoma, filtering surgery assisted by mitomycin-C and 5-FU may be recommended, when the IOP reduction is not satisfactory with anti-glaucoma medications.

Keyword

Normal-tension glaucoma; Medical treatment; Laser treatment; Filtration surgery

MeSH Terms

Anterior Chamber
Betaxolol
Brimonidine Tartrate
Carbonic Anhydrases
Filtering Surgery
Fluorouracil
Follow-Up Studies
Glaucoma*
Humans
Intraocular Pressure
Low Tension Glaucoma
Miosis
Mitomycin
Neuroprotective Agents
Optic Disk
Optic Nerve
Perfusion
Pilocarpine
Prostaglandins
Trabeculectomy
Venous Pressure
Visual Fields
Betaxolol
Carbonic Anhydrases
Fluorouracil
Mitomycin
Neuroprotective Agents
Pilocarpine
Prostaglandins

Reference

1. Shields MB, editor. Textbook of Glaucoma. 1998. 4th ed. Baltimore: Williams & Wilkins;158–166.

2. Lee JB, Cho YS, Choi YJ, Hong YJ. The prevalence of glaucoma in Korean adults. J Korean Ophthalmol Soc. 1993. 34:60–65.

3. Drance SM, Sweeney VP, Morgan RW, Feldman F. Studies of factors involved in the production of low-tension glaucoma. Arch Ophthalmol. 1973. 89:457–465.

4. Pillunat LE, Stodmeister R, Wilmanns I. Pressure compliance of the optic nerve head in low-tension glaucoma. Br J Ophthalmol. 1987. 71:181–187.

5. Drance SM, Douglas GR, Wijsman K. Response of blood flow to warm and cold in normal and low-tension glaucoma patients. Am J Ophthalmol. 1988. 105:35–39.

6. Gramer E, Althaus G, Leydhecker W. Site and depth of glaucomatous visual field defects in relation to the size of the neuroretinal edge zone of the optic disc in glaucoma. Klin Monastsbl Augenheilkd. 1986. 189:190–198.

7. Caprioli J, Spaeth GL. Comparison of the optic nerve head in high- and low-tension glaucoma. Arch Ophthalmol. 1985. 103:1145–1149.

8. Doyle A, Bensaid A, Lachkar Y. Central corneal thickness and vascular risk factors in normal tension glaucoma. Acta Ophthalmol Scand. 2005. 83:191–195.

9. Cartwright MJ, Anderson DR. Correlation of asymmetric damage with asymmetric intraocular pressure in normal tension glaucoma. Arch Ophthalmol. 1988. 106:898–900.

10. Collaborative normal-tension glaucoma study group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressure. Am J Ophthalmol. 1998. 126:487–497.

11. Lafuente MP, Villegas-Prez MP, Mayor S, Aguilera ME, Miralles de Imperial J, Vidal-Sanz M. Neuroprotective effects of brimonidine against transient ischemia-induced retinal ganglion cell death: a dose response in vivo study. Exp Eye Res. 2002. 74:181–189.

12. Harris A, Arend O, Chung HS, Kagemann L, Cantor L, Martin B. A comparative study of betaxolol and dorzolamide effect on ocular circulation in normal-tension glaucoma patients. Ophthalmology. 2000. 107:430–434.

13. Abedin S, Simmons RJ, Grant W. Progressive low-tension glaucoma: treatment to stop glaucomatous cupping and field loss when these progress despite normal intraocular pressure. Ophthalmology. 1982. 89:1–6.

14. Heyreh SS, Zimmermann MB, Podhajsky P, Alward WL. Nocturnal arterial hypotension and its role inoptic nerve head and ocular ischemic disorders. Am J Ophthalmol. 1994. 117:603–624.

15. Stamper RL, Lieberman MF, Drake MV. Becker-Shaffer's diagnosis and therapy of theglaucomas. 1999. 7th ed. St. Louis: The C.V. Mosby Company;309–310.